Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.58 |
| ▸ | XDH | P47989 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737611 | 0.90 | GABRA1 (0.59) | GABRA1GABRB2XDHPOLBMEN1 | |
| SCHEMBL1244606 | 0.90 | GABRA1 (0.59) | GABRA1GABRB2XDHPOLBMEN1 | |
| SCHEMBL1420694 | 0.89 | GABRA1 (0.64) | GABRA1GABRB2XDHPOLBMEN1 | |
| SCHEMBL11891611 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2XDHPOLBMEN1 | |
| SCHEMBL11287990 | 0.84 | GABRA1 (0.48) | GABRA1GABRB2XDHPOLBMEN1 | |
| SCHEMBL44699 | 0.82 | GABRA1 (0.48) | GABRA1GABRB2XDHPOLBMEN1 | |
| SCHEMBL6309438 | 0.81 | GABRA1 (0.61) | GABRA1GABRB2XDHPOLBMEN1 | |
| SCHEMBL1245217 | 0.79 | GABRA1 (0.48) | GABRA1GABRB2XDHPOLBMEN1 | |
| SCHEMBL30666305 | 0.79 | ALDH1A1 (0.59) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL28318476 | 0.79 | ALDH1A1 (0.59) | GABRA1GABRB2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9302967-B2 | Substituted cathechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-04-05 | — | — | US | claimed |
| US-20140135393-A1 | SUBSTITUTED CATHECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-05-15 | — | — | US | claimed |
| WO-2012140574-A1 | SUBSTITUTED CATECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-10-18 | — | — | WO | claimed |
| US-20120190738-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3) AND INDUCERS OF NITRIC OXIDE (NO) | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-07-26 | — | — | US | claimed |
| US-6057240-A | Aqueous surfactant solution method for stripping metal plasma etch deposited oxidized metal impregnated polymer residue layers from patterned metal layers | CHARTERED SEMICONDUCTOR MANUFACTURING, LTD. (SG) | 2000-05-02 | — | — | US | claimed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20140135393-A1 | SUBSTITUTED CATHECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-05-15 | — | — | US | disclosed |
| WO-2012140574-A1 | SUBSTITUTED CATECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012140574-A1 | SUBSTITUTED CATECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-10-18 | — | — | WO | disclosed |
| US-20120190738-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3) AND INDUCERS OF NITRIC OXIDE (NO) | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-07-26 | — | — | US | disclosed |
| US-20120190738-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3) AND INDUCERS OF NITRIC OXIDE (NO) | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-07-26 | — | — | US | disclosed |
| EP-2385934-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3) AND INDUCERS OF NITRIC OXIDE (NO) | Council of Scientific & Industrial Research (IN) | 2011-11-16 | — | — | EP | disclosed |
| US-8041964-B2 | Ultra low power wake-up circuit | COVIDIEN AG (CH) | 2011-10-18 | — | — | US | disclosed |
| WO-2010079423-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3) AND INDUCERS OF NITRIC OXIDE (NO) | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135393-A1 | SUBSTITUTED CATHECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA | IL5, IL4, IL33 | GABRA1 2052/4885GABRB2 2382/4885XDH 3518/4885 |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | GABRA1 2252/4885GABRB2 1299/4885XDH 679/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | GABRA1 3801/4885GABRB2 3665/4885XDH 978/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | GABRA1 2252/4885GABRB2 1299/4885XDH 679/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | GABRA1 3801/4885GABRB2 3665/4885XDH 978/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | GABRA1 3352/4885GABRB2 2968/4885XDH 793/4885 |
| US-20120190738-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE (PI3) AND INDUCERS OF NITRIC OXIDE (NO) | NOS2, NOS3, NOS1 | GABRA1 4024/4885GABRB2 2910/4885XDH 683/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | GABRA1 3352/4885GABRB2 2968/4885XDH 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.